In Korea, as in the United States and Japan, the recognition of patent infringement claims under the Doctrine of Equivalents (DoE) has been established by several key precedents. Recently, the Korean Supreme Court provided key guidance through detailed ruling standards for two of the three factors t

Last week the U.S. Food and Drug Administration approved an interchangeable biosimilar to insulin glargine, an approval notable because it is the first approved interchangeable biosimilar product. The product is Semglee (insulin glargine-yfgn), produced by Mylan Pharmaceuticals, Inc., and under this

Due to the impact of the COVID-19, people staying at home longer and the number of people for telecommuting has increased rapidly, not only the sales of interior decoration and furniture-related industries increased, but the number of furniture design patent applications in 2020 has also increased b

What’s in a name, they say. Well apparently a lot, when the column where the name is being mentioned corresponds to listing of invention in a Patent application. In the recent couple of years, the accredidation of Artificial Intelligence (AI) as an Inventor in an application for a Patent has been al

In its leading decision ‘Funkzellenzuteilung’ (allocation of radio cells), the German Federal Court of Justice ruled on the appeal in patent invalidity proceedings: the appeal must be brought against all parties to the dispute. An appeal only against individual plaintiffs is inadmissible.Patent in s